研究
2016 研究業績・論文発表
論文
Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, Nakagawa K.
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol. 77(5);997-1003 .2016
Tamiya M, Tamiya A, Kaneda H, Nakagawa K, Yoh K, Goto K, Okamoto H, Shimokawa T, Abe T, Tanaka H, Daga H, Takeda K, Hirashima T, Atagi S.
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Med Oncol.33(1);2.2016
Iwata T, Yoshino I, Yoshida S, Ikeda N, Tsuboi M, Asato Y, Katakami N, Sakamoto K, Yamashita Y, Okami J, Mitsudomi T, Yamashita M, Yokouchi H, Okubo K, Okada M, Takenoyama M, Chida M, Tomii K, Matsuura M, Azuma A, Iwasawa T, Kuwano K, Sakai S, Hiroshima K, Fukuoka J, Yoshimura K, Tada H, Nakagawa K, Nakanishi Y; West Japan Oncology Group.
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
Respir Res.17(1);90.2016
Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K.
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Lung Cancer. 99;186-93 .2016
Nonagase Y, Okamoto K, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Shimizu T, Tsurutani J, Nakagawa K.
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Anticancer Drugs. 2016 Mar;27(3):251-3.
Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Cancer. 122(7);1050-9.2016
Tanizaki J, Banno E, Togashi Y, Hayashi H, Sakai K, Takeda M, Kaneda H, Nishio K, Nakagawa K.
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Lung Cancer. 101;43054.2016
Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M.
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Jpn J Clin Oncol.46(5);462-7 .2016
Sakai K, Takeda M, Hayashi H, Tanaka K, Okuda T, Kato A, Nishimura Y, Mitsudomi T, Koyama A, Nakagawa K.
Clinical outcome of node-negative oligometastatic non-small cell lung cancer.
Thorac Cancer.7(6);670-675.2016
Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T; JCOG0605 investigators.
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol.17(8);1147-57 .2016
Takeda M, Nakagawa K.
Crizotinib for ALK rearrangement-positive non-small cell lung cancer patients with central nervous system metastasis
Translational Cancer Research 5(3);1-3.2016
Hayashi H, Nakagawa K.
Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation.
J Thorac Dis.8(10);E1311-E1316.2016
Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K.
Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Oncotarget. 7(36);58492-58499.2016
Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Cancer Sci. 107(11);1667-1676.2016
Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Clin Cancer Res. 2016 Jul 15;22(14):3663-71.
Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K
HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
Oncotarget. 2016;7(3):3453-60
Kawakami H, Yonesaka K
HER3 and its ligand, heregulin, as targets for cancer therapy.
Recent Patents on Anti-Cancer Drug Discovery 11(999);2016
Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Oncotarget.7(51);84860-84871.2016
Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS.
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
J Clin Oncol. 34(24);2858-65 .2016
Watanabe S, Hayashi H, Nakagawa K.
Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
Ann Transl Med.4(11);225.2016
Hisato Kawakami, Isamu Okamoto
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Gastric Cancer. 19(3);687-95.2016
Sinicrope FA, Okamoto K, Kasi PM, Kawakami H.
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
Clin Gastroenterol Hepatol.14(5);651-8.2016
Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA.
Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer.
Mol Cancer Ther.15(12);3015-3027.2016
Ryuge S, Masuda N, Yamamoto N, Takashi T, Murakami H, Takeda K, Daga H, Yonesaka K, Tsukuda H, Nakagawa K, Yanaka K, Kiura K, Takigawa N, Hida Y, Seto T, Yokoba M, Kudoh S, Takagaki T, Shono K, Kitagawa H, Kurihara T, Masahiro F.
Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function.
Cancer treatment and research communications9;81-87.2016
Hida T, Nakagawa K, Seto T, Satouchi M, Nishio M, Hotta K, Takahashi T, Ohe Y, Takeda K, Tatsuno M, Asakawa T, Shimada T, Tanaka T, Tamura T.
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ NSCLC with or without prior crizotinib therapy.
Cancer Sci. 107(11);1642-1646.2016
Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K.
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
Invest New Drugs.34(3);347-54 .2016
Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K.
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.
ESMO Open. 1(4);e000063.2016
Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K.
Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Clin Lung Cancer. 17(6);528-534.2016
Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC.
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
J Clin Oncol.34(27);3258-66.2016
Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y.
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
J Clin Oncol. 34(27);3248-57 .2016
Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K.
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Cancer Sci. 2016 Dec;107(12):1843-1850. doi: 10.1111/cas.13098
Nosaki K, Satouchi M, Kurata T, Yoshida T, Okamoto I, Katakami N, Imamura F, Tanaka K, Yamane Y, Yamamoto N, Kato T, Kiura K, Saka H, Yoshioka H, Watanabe K, Mizuno K, Seto T
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
Lung Cancer. 2016 Nov;101:1-8.
Tanizaki J, Hayashi H, Kimura M, Tanaka K, Takeda M, Shimizu S, Ito A, Nakagawa K.
Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
Lung Cancer. 102;44-48.2016
Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Cancer Sci. 2016 Aug;107(8):1134-40.
Ota T, Suzumura T, Sugiura T, Hasegawa Y, Yonesaka K, Makihara M, Tsukuda H, Tada T, Fukuoka M.
Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancer.
Clin Case Rep. 2016 Apr 1;4(5):481-5. doi: 10.1002/ccr3.547. eCollection 2016 May
Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K.
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Invest New Drugs.34(3);394-6 .2016
Ueda H, Hayashi H, Kudo K, Takeda M, Nakagawa K.
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Invest New Drugs.34(6);797-799.2016
Sakai H, Hayashi H, Iwasa T, Hasegawa Y, Takeda M, Kazuhiko N.
Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.
ESMO Open. ;1-4.2016
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC study group.
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Lancet Oncol. 17(1);33086.2016
Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Siato M. A, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S and Negoro S.
The Efficacy and Safety of Sterile Graded Talc in Pleurodesis for Malignant Pleural Effusion: Phase II study
Lancet Oncol. 17(1);33086.2016
Takegawa N, Hayashi H, Iizuka N, Takahama T, Ueda H, Tanaka K, Takeda M, Nakagawa K.
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.
Ann Oncol. 27(5);953-5.2016
Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K.
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Clin Lung Cancer.(16);30139-5 .2016
Haratani K, Hayashi H, Watanabe S, Kaneda H, Yoshida T, Takeda M, Shimizu T, Nakagawa K.
Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib.
Ann Oncol.27(1);200-2.2016
Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB.
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
PLoS One. 2016 Jan 20;11(1):e0147344.